Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
61.43 USD | -3.67% | -9.73% | +11.41% |
May. 16 | Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing | MT |
May. 10 | ANI Pharmaceuticals Seeks M&A | CI |
Financials (USD)
Sales 2024 * | 539M | Sales 2025 * | 577M | Capitalization | 1.19B |
---|---|---|---|---|---|
Net income 2024 * | 33M | Net income 2025 * | 41M | EV / Sales 2024 * | 2.25 x |
Net Debt 2024 * | 20.98M | Net cash position 2025 * | 44.87M | EV / Sales 2025 * | 1.99 x |
P/E ratio 2024 * |
39.2
x | P/E ratio 2025 * |
25.6
x | Employees | 642 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.47% |
Latest transcript on ANI Pharmaceuticals, Inc.
1 day | -3.67% | ||
1 week | -9.73% | ||
Current month | -6.92% | ||
1 month | -6.19% | ||
3 months | +2.86% | ||
6 months | +19.54% | ||
Current year | +11.41% |
Managers | Title | Age | Since |
---|---|---|---|
Nikhil Lalwani
CEO | Chief Executive Officer | 46 | 20-09-07 |
Stephen Carey
DFI | Director of Finance/CFO | 53 | 16-05-05 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Haughey
BRD | Director/Board Member | 60 | 18-04-30 |
Antonio Pera
BRD | Director/Board Member | 66 | 20-08-05 |
David Nash
BRD | Director/Board Member | 68 | 18-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 11 M€ | -6.03% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 61.43 | -3.67% | 153,427 |
24-05-16 | 63.77 | -1.62% | 132,119 |
24-05-15 | 64.82 | -1.83% | 150,915 |
24-05-14 | 66.03 | -1.95% | 155,491 |
24-05-13 | 67.34 | -1.04% | 140,177 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.41% | 1.19B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- ANIP Stock